Conference Proceedings

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3-ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Natasha S Anstee, Giovanna Pomilio, Mark Levis, Sarah MacRaild, Michael Murray, Tristan Rawling, Glen A Kennedy, Andrew Grigg, Anthony Schwarer, Anoop Kumar Enjeti, James D'Rozario, Paula Marlton, Ian Bilmon, Adam Ivey, Doen Ming Ong, Andrew W Roberts, Andrew H Wei

Blood | American Society of Hematology | Published : 2020


Introduction The Australasian Leukaemia and Lymphoma Group (ALLG) conducted a randomized trial (AMLM16) combining the FLT3 inhibitor sorafenib (SOR) or placebo (PBO) with intensive induction and consolidation chemotherapy, followed by 12 months of maintenance therapy in patients with FLT3-ITD mutant AML. The clinical results of the AMLM16 study are detailed in a companion abstract co-submitted to ASH 2020. We hypothesized that the optimal time to administer sorafenib would be d4-10 of induction in order to limit overlap with anthracyclines on d1-3 and to avoid high FLT3 ligand (FLT3L) levels beyond d10, which could abrogate FLT3 on-target activity and diminish the therapeutic ..

View full abstract